相关实验视频

Updated: Jun 4, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

苏帕格卢提德可以缓解子中自发MASH的肝肥胖症

Qinghua Wang^1,2, Yue Zhou³, Yunzhi Ni³

¹Shanghai Innogen Pharmaceutical Co., Ltd, Shanghai, China. dr.qwang@innogenpharm.com.

Diabetology & metabolic syndrome

|December 19, 2024

概括

长期作用的GLP-1模拟物Supaglutide有效地减少了MASH的肝脂肪,并改善了MASH的代谢功能障碍. 这种新型疗法在治疗代谢功能障碍相关的脂肪肝炎方面表现有前途.

科学领域:

内分泌学在内分泌学.
肝病学肝病学是一种肝病学.
药理学药理学是指药理学的学科.

背景情况:

类似葡萄糖的1 (GLP-1) 对于葡萄糖平衡至关重要,但其半衰期很短,限制了治疗用途.
苏帕格卢提德是一种新型的长效GLP-1模拟剂,此前在糖尿病和肥胖模型中显示有好处.
这项研究评估了supaglutide在非人类灵长类动物中具有自发代谢功能障碍相关的脂肪肝炎 (MASH) 的疗效.

研究的目的:

为了研究supaglutide在MASH的 rhesus子中的治疗效果.
评估supaglutide对肝脏脂肪积累,肝脏病理和代谢参数的影响.

主要方法:

15只经活检确认MASH的 rhesus子每周接受皮下注射supaglutide (50或150μg/kg) 或安慰剂3个月.
使用MRI-PDFF测量肝脏脂肪含量.
通过活检和血液检查评估肝脏病理和代谢参数.

主要成果:

苏帕格卢提德显著减少了40%的肝脏脂肪积累 (MRI-PDFF,P <0.001与0.001对比). 这是安慰剂).
治疗缓解了肝肥胖症 (NAFLD活动得分,P < 0.001与0.001对比. 没有恶化的纤维化.
苏帕格卢提德改善了脂质谱,血糖控制,减轻了体重,并减少了剂量依赖的食物摄入量.

结论:

在MASH子中,Supaglutide对肝脏脂肪和代谢功能障碍有显著的有益影响.
这些发现支持supaglutide作为MASH的治疗剂的潜力.

关键词:

类似葡萄糖的1 类似葡萄糖1 肝脏活检活检是什么意思肝脏脂肪含量肝脏脂肪含量与代谢功能障碍相关的脂肪肝炎.这就是Supaglutide的含量.

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...